X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PPL-138 is the small molecule that meets all of our criteria for a potent, safe, non-addicting analgesic and also effective treatment of post-traumatic stress disorder and decreased alcohol consumption.
Lead Product(s): Naltrexone Analog
Therapeutic Area: Psychiatry/Psychology Product Name: PPL-138
Highest Development Status: PreclinicalProduct Type:
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Funding from the grant will support the study of company’s lead compound, PPL-138, for the treatment of cocaine use disorder (CUD) and the cost of advancing PPL-138 through its remaining preclinical studies and through Phase 1 human clinical trials.
Lead Product(s): PPL-138
Therapeutic Area: Psychiatry/Psychology Product Name: PPL-138
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $8.7 million Upfront Cash: Undisclosed
Deal Type: Funding October 06, 2022
Details:
Both compounds have also shown promise in preclinical studies as treatments for opioid addiction (PPL-103) and cocaine addition (PPL-138) and the company is pursuing these indications as well.
Lead Product(s): PPL-138
Therapeutic Area: Neurology Product Name: PPL-138
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Netcapital
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
